

Program

5th ForTra Workshop for Translational Research



11th and 12th July 2023



Goethe University of Frankfurt,
Campus Westend, Casino-Gebäude
Theodor-W.-Adorno-Platz 1,
60323 Frankfurt am Main,
Germany

Day 1 (11th of July, 2023):

11.30 – 12.30 Get together, lunch (finger food)

12.30 – 12.45 **Prof. Martin Zörnig** (*ForTra gGmbH*, Frankfurt): Welcome

Session 1 (Chairperson Prof. Martin Zörnig):

12.45 – 13.25 **Dr. Martina Schübler-Lenz** (*Paul-Ehrlich-Institute*, Langen):
“From research to market approved medicines – the regulatory perspective”

13.25 – 14.05 **Christian Lange** (*biosafety4u.berlin GmbH*, Berlin):
“Introduction to GXP: GMP and GLP – what is needed for clinical translation?”

14.05 – 14.25 **Prof. Christoph Schindler** (*MHH Early Clinical Trial Unit*, Hannover):
“Translation and early phase research at MHH”

14.25 – 14.45 **Dr. Frank Behrens** (*Research Division Clinical Research, Fraunhofer-Institut für Translationale Medizin und Pharmakologie (ITMP)*, Frankfurt): “Introduction of the Research Division Clinical Research and its in-house clinical phase 1 unit of the ITMP”

14.45 – 15.05 Coffee break

Session 2 (Chairperson Dr. Ansgar Santel (Pantherna Therapeutics GmbH)):

15.05 – 15.35 **Prof. Jochen Hampe** (*Else Kröner-Fresenius-Zentrum für Digitale Gesundheit*, Dresden): “EKfZ for Digital Health and BMBF Cluster SEMECO: a platform for MedTech innovation with the electronics industry”

15.35 – 16.05 **Florian Tolkmitt** (*PRO-LIANCE GLOBAL SOLUTIONS GmbH*, Münster): “From a medical device idea to market – the regulatory perspective”

16.05 – 16.20 **Prof. Manuel Kaulich** (*Vivlion GmbH*, Frankfurt): “The Vivlion Story: Successful international business development starting from university research”

16.20 – 16.35 **Dr. Stefan Glögger** (*Max Planck Institute for Multidisciplinary Sciences*, Göttingen): “Rapidly signal-enhanced metabolic MRI – a fast track to better cancer diagnostics” (funded by *ForTra*)

16.35 – 16.55 Coffee break

Session 3 (Chairperson Prof. Martin Zörnig):

16.55 – 17.10 **PD Dr. Antonia Busse** (*Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumورimmunologie, Charité – Universitätsmedizin Berlin*): “Precision immunotherapy: Mutation-specific TCR-T cell therapy for MyD88L265P mutated lymphoma – GMP-grade vector production and establishment of TCR-T cell manufacturing” (funded by *ForTra*)

- 17.10 – 17.25 **Dr. Jonas Heitmann** (*Department of Medicine, Clinical Collaboration Unit Translational Immunology, University Hospital Tübingen*): “CC-1, a bispecific PSMAxCD3 antibody – Current status of the clinical trials” (funded by *ForTra*)
- 17.25 – 18.00 **Panel discussion**
“When does a translational project become an investment case? Different perspectives on investment strategies”
Discussion leader: **Dr. Axel Polack** (*Polack Holding GmbH*)
Further participants:
Dr. Martin Raditsch (*CARMA FUND Management GmbH, Frankfurt/München*)
Michael Krebs (*KHAN Technology Transfer Fund I, Dortmund*)
Christoph Broja (*EQT Life Sciences, Stockholm*)
Dr. Frank Hensel (*High-Tech Gründerfonds, Bonn*)
Dr. Patrick Pfeffer (*Aescuvest, Frankfurt*)
- 18.00 – 18.45 Keynote Lecture
Prof. Gerard Evan (*The Francis Crick Institute, London*):
“Where cancers come from and how to make them go away”
- 18.45 – 19.30 Dinner und Networking
- 20.00 Speakers' Dinner

Gerard Evan

Although cancers are very diverse and heterogenous, they are nonetheless underpinned by a limited ensemble of shared, common processes. The hope is that identifying and understanding such underlying commonalities will lead to novel cancer therapies that may be broadly applied to diverse patients and many cancer types.

Gerard obtained his BA in Biochemistry from the University of Oxford in 1997 and his Ph.D. in 1981 in molecular immunology from the MRC Laboratory of Molecular Biology at the University of Cambridge. From 1982-4, he was a post-doctoral fellow with J. Michael Bishop at the University of California San Francisco studying the molecular biology of cancer, returning to take up a Research Fellowship at Downing College Cambridge and Assistant Membership of the Ludwig Institute for Cancer Research. In 1988, he moved to the Imperial Cancer Research Fund Laboratories in London as a Senior, then Principal, Scientist.

He was elected to EMBO and to the Royal Society's Napier Research Professorship in 1996 and to fellowship of the Academy of Medical Sciences in 1999. That same year he took up a Distinguished Chair in Cancer Biology at the University of California San Francisco and was appointed Professor of Pathology in 2007. In 2009 he returned to the UK to become Sir William Dunn Professor and Head of Biochemistry at the University of Cambridge. In 2022, Gerard joined the Francis Crick Institute and was appointed Professor of Cancer Biology at Kings College London.



Day 2 (12th of July, 2023):

Session 4 (Chairperson Dr. Ansgar Santel):

- 10.00 – 10.40 **Dr. Kirstin Schilling** (*Innovectis*, Frankfurt):
“Who is inventor, and who owns the patent?”
- 10.40 – 11.00 **Dr. Sebastian Hückesfeld** (*Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR) Projektträger*, Bonn): “Translational Funding Measures of the Federal Ministry of Education and Research (BMBF)”
- 11.00 – 11.20 **Dr. Eckard Picht** (*Deutsche Forschungsgemeinschaft*, Bonn):
“Funding opportunities for translational research projects offered by the German Research Foundation”
- 11.20 – 11.40 **Dr. Lars Jöckel** (*Deutsche Krebshilfe*, Bonn): “German Cancer Aid: Funding Opportunities in Translational Oncology.”
- 11.40 – 12.00 **Bernhard Knappe** (*Wilhelm Sander-Stiftung*, Neustadt an der Donau):
“Funding possibilities of the Wilhelm Sander-Stiftung”
- 12.00 – 12.20 **Barbara Diehl** (*Bundesagentur für Sprung-Innovationen*, Leipzig):
“SPRIND wants you to succeed! Introducing the funding and support mechanisms of the Federal Agency for Disruptive Innovation”
- 12.20 – 13.30 Lunch

Session 5 (Chairperson Prof. Martin Zörnig):

- 13.30 – 13.45 **Prof. Achim Hoerauf** (*Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Universitätsklinikum Bonn*): “Corallopyronin A – a natural antibiotic against helminths, STI and Staphylococci” (funded by *ForTra*)
- 13.45 – 14.00 **Prof. Andreas Peschel** (*Interfakultäres Institut für Mikrobiologie und Infektionsmedizin (IMIT), Eberhard Karls Universität Tübingen*):
“The microbiome as a source of and target for novel antibacterial strategies” (funded by *ForTra*)
- 14.00 – 14.45 Keynote Lecture
Dr. Sean Fielding (*University of Exeter*):
“From Translation to Trading – What can you do next to get your idea into market?”
- 14.45 – 15.00 **Prof. Martin Zörnig**: Concluding remarks, farewell

Sean Fielding

Doing the research to test a hypothesis and then generating the data to demonstrate use in a particular situation can often seem like enough of a challenge for scientists. But if you really want your idea to help society then it will have to attract further investment and be adopted by business. What is the role of the scientist in making this happen and what can you do to make it more likely that your idea succeeds?

Sean is the former Director of Innovation, Impact and Business at the University of Exeter in the UK and is currently running global marketing operations for the University. He was responsible for a team that manages projects with an annual value of £100M, connecting organisations to the University, creating new business opportunities and generating new innovation.

Sean was Chair of the UK's national association for knowledge exchange professionals, PraxisAuril (2018-2020), Vice-President of the Association of European Science and Technology Transfer Professionals (ASTP), and a board member of the global Alliance of Technology Transfer Professionals (ATTP) which promotes the RTTP World-wide standard for knowledge transfer professionals. He was chair of SETSquared, the World's no 1 University business Incubator and he has established two innovation centres and a Science Park and led several entrepreneurship programmes.

Sean has had 30 years' experience of strategic management in higher education as well as having been Managing Director and Director of several companies. He previously set up and led joint-ventures for commercialising and marketing national and international HE services.

